Clinicians ‘Game Planning’ for Pediatric Cancer Drug Shortages

News
Video

A childhood cancer specialist discusses how oncology drug shortages may affect the treatment of children with cancer.

Dr. Mallorie B. Heneghan, an assistant professor of pediatrics at the University of Utah and in the division of pediatric hematology/oncology at Primary Children´s Medical Center, told CURE® that she has been seeing a lot of the chemotherapy drug shortage lately — which poses a specific problem for her pediatric patients with blood cancers.


“That's kind of that kind of catch 22-of pediatric cancer, (it) is rare and so we're not kind of a big market space for pharmaceutical companies,” she said. “But I would say that it's so critical that we have the right drugs to treat our patients, because we have such great outcomes. I'm specifically a leukemia/ lymphoma doctor, and with good chemotherapy medications we're seeing patients going on to live decades. And so, making sure that we have the tools are available (is important), do we have access to them?

“So, I can think of a couple different chemotherapy medications off the top of my head, then unfortunately, we are in a place that we've been able to secure supply for our patients, but we've had certainly several conversations as an institution about game-planning for what happens if we're not able to secure that. And so, we've had to be very proactive about that, which takes time and energy on everyone's behalf. And I hope we can continue to do that so that we can secure access for our patients. But I do worry.”

For instance, Heneghan said, there is currently a shortage of vinblastine (which has recently shown promising study results for the treatment of Hodgkin lymphoma) and concerns of an impending vincristine shortage down the line.

More CURE® coverage of the chemotherapy shortage:

“Those are both critical drugs in our treatment plan,” she said. “And I think I've heard the methotrexate shortage is over now, but that was certainly one that was very scary to me (as) someone that treats a lot of leukemia (and) again, a drug (that) we know really works. And unfortunately, if we just can't get access to it, we can't treat our patients.”

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Sue Friedman in an interview with CURE
Dr. Giles in an interview with CURE